52.69 -0.16 (-0.30%)
After hours: 4:58PM EST
|Bid||52.57 x 1000|
|Ask||52.69 x 1400|
|Day's Range||52.70 - 53.53|
|52 Week Range||46.94 - 70.05|
|Beta (3Y Monthly)||1.37|
|PE Ratio (TTM)||234.89|
|Earnings Date||Feb 4, 2019 - Feb 8, 2019|
|Forward Dividend & Yield||1.60 (3.16%)|
|1y Target Est||59.47|
Nektar Therapeutics bounded higher Monday after its immunotherapy combination with Bristol-Myers Squibb showed promise as a melanoma treatment.
Nektar Therapeutics (NKTR) incurred general and administrative expenses of $18.72 million in the third quarter of 2018 as compared with $12.06 million in the third quarter of 2017. Nektar Therapeutics expects general and administrative expenses in fiscal 2018 to be higher than they were in fiscal 2017.
Nektar Therapeutics’ (NKTR) interest expense decreased marginally to $5.44 million in the third quarter of 2018 as compared with $5.54 million in the year-ago period. Its net interest and other income increased from $1.6 million in the third quarter of 2017 to $11.85 million in the third quarter of 2018 due to higher interest income from investments in debt securities that the company purchased with $1.85 billion it received from collaboration with Bristol-Myers Squibb (BMY) in April 2018. Nektar Therapeutics incurred a net loss of $96.14 million in the third quarter of 2018 as compared with net income of $60.87 million in the year-ago period.
Nektar Therapeutics’ (NKTR) non-cash royalty revenue associated with the sale of future royalties increased from $8.07 million in the third quarter of 2017 to $8.37 million in the third quarter of 2018. The significant drop in Nektar’s total revenues was attributable to a decline in license, collaboration, and other revenues, which decreased from $131.11 million in the third quarter of 2017 to $4.87 million in the third quarter of 2018.
According to Willie Delwiche, investment strategist at R.W. Baird, “Oil being down could be a sign that the global economy is in a tough spot.” “The initial reaction to lower oil prices has been that they’ll be a boon for the middle class,” Delwiche said that the view could be inaccurate considering that consumer confidence doesn’t have more chances to grow, and because a smaller part of the American consumer’s budget goes to gasoline than it has in the previous years. The stock recorded a trading volume of 1,456,948 shares, which was above its three months average volume of 998,535 shares. On Friday, shares of Bristol-Myers Squibb recorded a trading volume of 8,107,392 shares, which was above the three months average volume of 7,213,656 shares.
Repligen stock is on a rampage this year as it outperforms broad medical-products stocks. The bioprocessing firm has completely transformed, its CEO says.
Catalyst (CPRX) provides pipeline update and the FDA sets action date of Nov 28, 2018 for its lead pipeline candidate, Firdapse during the third quarter of 2018.
Keryx's (KERX) sole marketed product generates sales of $26.6 million in the third quarter, up 96% from the year-ago quarter.
The Zacks Analyst Blog Highlights: DXP Enterprises, Bristol-Myers Squibb, EnPro Industries, Illumina and NetApp
Lilly (LLY) and AstraZeneca (AZN) report third-quarter results. Pfizer (PFE) gains FDA approval for a new cancer medicine.
NEW YORK, NY / ACCESSWIRE / November 9, 2018 / U.S. stocks retreated on Thursday after the Fed left interest rates unchanged and signaled that it would continue to tighten monetary policy at a gradual pace. Charlie Ripley, senior investment strategist at Allianz Investment Management said that, “With no press conference or expectation for policy change, most market participants viewed the November FOMC meeting as more of a non-event. “With only minimal changes to the statement the Fed is remaining vague about policy changes going forward and likely giving the committee more optionality in a changing market environment,” he added.
Bristol-Myers Squibb (BMY) closed the most recent trading day at $52.81, moving -0.34% from the previous trading session.
FRANKFURT/LONDON (Reuters) - German drugmaker Stada (STAGn.DE) and Italian healthcare company Angelini are the only industry players to be shortlisted to make final bids for Bristol-Myers Squibb's (BMY.N) French over-the-counter drugs business, four sources close to the deal said. Two private equity firms, CVC Capital Partners and PAI Partners, have also made it through to the final round of the auction for UPSA, the maker of Dafalgan and Efferalgan painkillers, the sources told Reuters.
FRANKFURT/LONDON, Nov 8 (Reuters) - German drugmaker Stada and Italian healthcare company Angelini are the only industry players to be shortlisted to make final bids for Bristol-Myers Squibb's French over-the-counter drugs business, four sources close to the deal said. Two private equity firms, CVC Capital Partners and PAI Partners, have also made it through to the final round of the auction for UPSA, the maker of Dafalgan and Efferalgan painkillers, the sources told Reuters.
Immune Design (IMDZ) posts narrower-than-expected loss and misses revenue estimates in the third quarter of 2018. It expects to have cash to fund operations in 2021.
Alnylam (ALNY) incurs wider-than-expected loss year over year in the third quarter of 2018 and reiterates guidance for the year.
Bristol-Myers (BMY) signs a contract with Infinity Pharmaceuticals to evaluate the combination of its Pd-1 inhibitor Opdivo and Infinity's IPI-549 for treating advanced urothelial cancer